Keep your eye on insurance coverage and side effects of LLY and NVO meds for weight loss, as well as GILD’s presentation at ADA conference beginning tomorrow, 6/21/2024. I have stayed out of LLY and NVO while enjoying our substantial gain in 7,550 shares of NVDA (mentioned in your WSJ story link; I purchased NVDA in 2009 at split adjusted basis of $0.434 per share). We also have 3200 shares of GILD that traded + >$5 per share today, exact reasons unknown.
News 
Market Data 
Discover 
